Table 1.
Characteristics of studies reporting on outcomes related to BMs in patients with HER2-positive BC.
| Anti-HER2 Agent | Authors | Study | Population | Outcomes related to BM |
|---|---|---|---|---|
| Trastuzumab | Brufsky et al. (23) | Prospective | Newly diagnosed HER2+ MBC | Time to BM progression, OS |
| Trastuzumab | Olson et al. (24) | Retrospective | HER2+ BC | Incidence of BM as first metastatic site |
| Pertuzumab + high dose trastuzumab | Lin et al. (25) | Prospective | HER2+ BCBM after RT | CNS ORR |
| Trastuzumab + pertuzumab + taxane | Gamucci et al. (26) | Retrospective | HER2+ MBC | ORR, PFS, OS |
| Pertuzumab + capecitabine + trastuzumab | Urruticoechea et al. (27) | Prospective | HER2+ MBC | PFS, OS |
| Lapatinib | Lin et al. (28) | Prospective | HER2+ BCBM, prior trastuzumab and RT | CNS ORR, PFS, OS |
| Lapatinib + capecitabine | Bachelot et al. (29) | Prospective | HER2+ BC with untreated BM | CNS ORR, PFS |
| Lapatinib + WBRT | Lin et al. (30) | Prospective | HER2+ BCBM | Maximum tolerated dose, CNS ORR, PFS, OS |
| Neratinib +capecitabine | Freedman et al. (31) | Prospective | HER2+ BCBM | CNS ORR, PFS, OS |
| Neratinib + paclitaxel | Awada et al. (32) | Prospective | HER2+ MBC | Incidence BM, Time to BM, Time to BM progression |
| Pyrotinib + capecitabine | Yan et al. (33) | Prospective | HER2+ BCBM | CNS ORR, the time to CNS response, PFS, OS |
| Tucatinib + trastuzumab + capecitabine | Murthy et al. (34) | Prospective | HER2+ MBC, prior treated with trastuzumab, pertuzumab, and trastuzumab emtansine | PFS, OS, ORR |
| T-DM1 | Krop et al. (35) | Retrospective | HER2+ MBC | Incidence of BM, PFS, OS |
| T-DM1 | Montemurro et al. (36) | Prospective | HER2+ BCBM | CNS ORR, PFS, OS |
| DS-8201 | Modi et al. (37) | Prospective | HER2+ MBC, previous treated with T-DM1 | PFS |
| DS-8201 | Cortés et al. (38) | Prospective | HER2+ MBC | PFS, OS, ORR |
BC, breast cancer; BCBM, breast cancer brain metastases; BM, brain metastasis; CNS, central nervous system; DS-8201, trastuzumab deruxtecan; HER2, human epidermal growth factor receptor 2; MBC, metastatic breast cancer; OS, overall survival; ORR, objective response rate; PFS, progression-free survival; RT, radiotherapy; T-DM1, trastuzumab emtansine; WBRT, whole brain radiotherapy.